RPRX · Company research
Royalty Pharma plc (RPRX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
25records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Royalty Pharma Announces Fourth-Quarter 2026 Dividend of $0.235 Per Class A Ordinary Share - Quiver Quantitative | Royalty Pharma Announces Fourth-Quarter 2026 Dividend of $0.235 Per Class A Ordinary Share Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 16, 2026 | neutral | 0 | 0.6 |
| Shareholders are set to get 23.5 cents per share from Royalty Pharma on Dec. 10. - Stock Titan | Shareholders are set to get 23.5 cents per share from Royalty Pharma on Dec. 10. Stock Titan | View source ↗ | Stock Titan | Oct 16, 2026 | neutral | 0 | 0.6 |
| Royalty Pharma PLC $RPRX Shares Purchased by Triasima Portfolio Management inc. - MarketBeat | Royalty Pharma PLC $RPRX Shares Purchased by Triasima Portfolio Management inc. MarketBeat | View source ↗ | MarketBeat | Oct 16, 2026 | neutral | 0 | 0.6 |
| If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today - Benzinga | If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today Benzinga | View source ↗ | Benzinga | Oct 15, 2026 | neutral | 0 | 0.6 |
| Royalty Pharma (NASDAQ:RPRX) Stock Jumps 3.3% - Here's Why - MarketBeat | Royalty Pharma (NASDAQ:RPRX) Stock Jumps 3.3% - Here's Why MarketBeat | View source ↗ | MarketBeat | Oct 14, 2026 | neutral | 0 | 0.6 |
| (RPRX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily | (RPRX) Price Dynamics and Execution-Aware Positioning Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 14, 2026 | neutral | 0 | 0.6 |
| 113,760 Royalty Pharma PLC $RPRX Shares Sold by Cooper Investors PTY Ltd. - MarketBeat | 113,760 Royalty Pharma PLC $RPRX Shares Sold by Cooper Investors PTY Ltd. MarketBeat | View source ↗ | MarketBeat | Oct 13, 2026 | neutral | 0 | 0.6 |
| Royalty Pharma PLC (NASDAQ:RPRX) Stock Has Average Target Price of $61.57 According to Brokerages - MarketBeat | Royalty Pharma PLC (NASDAQ:RPRX) Stock Has Average Target Price of $61.57 According to Brokerages MarketBeat | View source ↗ | MarketBeat | Oct 13, 2026 | neutral | 0 | 0.6 |
| Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance Singapore | Royalty Pharma plc (RPRX) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 13, 2026 | neutral | 0 | 0.6 |
| Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? | The Invesco Biotechnology & Genome ETF (PBE) is a passively managed fund with $418.99 million in assets, offering exposure to the Healthcare-Biotech sector. With a 0.59% expense ratio and 1.38% dividend yield, it returned 18.51% over the past year but carries higher risk with a beta of 0.70 and 20.16% standard deviation. The fund holds 33 concentrated positions with top holdings including Royalty Pharma, Gilead Sciences, and Biogen. PBE received a Zacks ETF Rank of 3 (Hold), with larger competitors XBI and IBB offering lower expense ratios. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.333 | 1 |
| Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? | The Invesco Biotechnology & Genome ETF (PBE) is a passively managed fund with $418.99 million in assets, offering exposure to the Healthcare-Biotech sector. With a 0.59% expense ratio and 1.38% dividend yield, it returned 18.51% over the past year but carries higher risk with a beta of 0.70 and 20.16% standard deviation. The fund holds 33 concentrated positions with top holdings including Royalty Pharma, Gilead Sciences, and Biogen. PBE received a Zacks ETF Rank of 3 (Hold), with larger competitors XBI and IBB offering lower expense ratios. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.333 | 1 |
| Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance UK | Royalty Pharma plc (RPRX) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 13, 2026 | neutral | 0 | 0.6 |
| Royalty Pharma plc (RPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada | Royalty Pharma plc (RPRX) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 13, 2026 | neutral | 0 | 0.6 |
| RPRX Stock Fundamentals & Key Ratios - Pluang | RPRX Stock Fundamentals & Key Ratios Pluang | View source ↗ | Pluang | Oct 12, 2026 | neutral | 0 | 0.6 |
| A live call on Royalty Pharma's third-quarter results is set for 8 a.m. Nov. 4 - Stock Titan | A live call on Royalty Pharma's third-quarter results is set for 8 a.m. Nov. 4 Stock Titan | View source ↗ | Stock Titan | Oct 9, 2026 | neutral | 0 | 0.6 |
| Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance Australia | Royalty Pharma plc (RPRX) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 9, 2026 | neutral | 0 | 0.6 |
| Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again | Royalty Pharma (RPRX) has demonstrated a consistent track record of beating earnings estimates, with an average surprise of 5.25% over the past two quarters. The company's positive Earnings ESP of +0.21% combined with its Zacks Rank #3 (Hold) suggests another potential earnings beat is likely, as stocks with this combination historically beat consensus estimates nearly 70% of the time. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again | Royalty Pharma (RPRX) has demonstrated a consistent track record of beating earnings estimates, with an average surprise of 5.25% over the past two quarters. The company's positive Earnings ESP of +0.21% combined with its Zacks Rank #3 (Hold) suggests another potential earnings beat is likely, as stocks with this combination historically beat consensus estimates nearly 70% of the time. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again | Royalty Pharma (RPRX) has demonstrated a consistent track record of beating earnings estimates, with an average surprise of 5.25% over the past two quarters. The company's positive Earnings ESP of +0.21% combined with its Zacks Rank #3 (Hold) suggests another potential earnings beat is likely, as stocks with this combination historically beat consensus estimates nearly 70% of the time. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| At $57.10 a share, Royalty Pharma (RPRX) EVP Marshall Urist sells 4,126 shares. - Stock Titan | At $57.10 a share, Royalty Pharma (RPRX) EVP Marshall Urist sells 4,126 shares. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Officer Marshall Urist proposes selling 4,126 Royalty Pharma (RPRX) shares. - Stock Titan | Officer Marshall Urist proposes selling 4,126 Royalty Pharma (RPRX) shares. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? | Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space. | View source ↗ | The Motley Fool | Oct 1, 2026 | bullish | 0.2 | 1 |
| Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? | Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space. | View source ↗ | The Motley Fool | Oct 1, 2026 | bullish | 0.2 | 1 |
| Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run - Yahoo Finance | Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run Yahoo Finance | View source ↗ | Yahoo Finance | Sep 23, 2026 | neutral | 0 | 0.6 |
| Royalty Pharma (RPRX) Stock Revenue Strength Masks Thin Earnings - Simply Wall Street | Royalty Pharma (RPRX) Stock Revenue Strength Masks Thin Earnings Simply Wall Street | View source ↗ | Simply Wall Street | Aug 6, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.